Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity

Brain Tumor Pathology

Volumn 27, Issue 2, 2010, Pages 89-94

  Takano, Shingo ^a   Mashiko, Ryota ^a   Osuka, Satoru ^a   Ishikawa, Eiichi ^a   Ohneda, Osamu ^b   Matsumura, Akira ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Bevacizumab; Irinotecan; Malignant glioma; Metalloproteinase; Zymogram

Indexed keywords

BEVACIZUMAB; GADOLINIUM; GELATINASE A; GELATINASE B; IRINOTECAN; NIMUSTINE; STROMAL CELL DERIVED FACTOR 1; TEMOZOLOMIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BRAIN METASTASIS; BRAIN VENTRICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; UPREGULATION; URINALYSIS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN; BRAIN NEOPLASMS; CHEMOKINE CXCL12; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM INVASIVENESS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 78149400015     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-010-0271-y     Document Type: Article

References (17)

1. M.C. Chamberlain 2008 Bevacizumab plus irinotecan in recurrent glioblastoma J Clin Oncol 26 1012 1013 10.1200/JCO.2007.15.1605 18281677 (Pubitemid 351398097)
2. S. Chowdhary E.T. Wong 2008 Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme: improvement over available therapy? Nat Clin Pract Neurol 4 242 243 10.1038/ncpneuro0712 18212790 (Pubitemid 351639540)
3. J.J. Vredenburgh A. Desjardins J.E. Herndon II, et al. 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 1:CAS:528:DC%2BD2sXhtlCgsLjF 10.1200/JCO.2007.12.2440 17947719 (Pubitemid 350086473)
4. G. Bergers D. Hanahan 2008 Modes of resistance to antiangiogenic therapy Nat Rev Cancer 8 592 603 1:CAS:528:DC%2BD1cXovV2lsrk%3D 10.1038/nrc2442 18650835
5. K. Lamszus P. Kunkel M. Westphal 2003 Invasion as limitation to anti-angiogenic glioma therapy Acta Neurochir Suppl 88 169 177 1:STN:280:DC%2BD3svmvFeqsQ%3D%3D 14531575
6. M.A. Moses D. Wiederschain K.R. Loughlin, et al. 1998 Increased incidence of matrix metalloproteinases in urine of cancer patients Cancer Res 58 1395 1399 1:CAS:528:DyaK1cXit1eksro%3D 9537238
7. S. Takano H. Kamiyama K. Tsuboi, et al. 2004 Angiogenesis and antiangiogenic therapy for malignant gliomas Brain Tumor Pathol 21 69 73 1:CAS:528:DC%2BD2MXhtlSjsLzM 10.1007/BF02484513 15700836 (Pubitemid 39518149)
8. S. Ananthnarayan J. Bahng J. Roring, et al. 2008 Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol 88 339 347 10.1007/s11060-008-9573-x 18389177
9. A. Narayana P. Kelly J. Golfinos, et al. 2009 Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival J Neurosurg 110 173 180 10.3171/2008.4.17492 18834263
10. A.D. Norden G.S. Young K. Setayesh, et al. 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 1:CAS:528:DC%2BD1cXitlyqs7o%3D 10.1212/01.wnl.0000304121.57857.38 18316689
11. R.M. Zuniga R. Torcuator R. Jain, et al. 2009 Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J Neurooncol 91 329 336 1:CAS:528:DC%2BD1MXjvFemtQ%3D%3D 10.1007/s11060-008-9718-y 18953493
12. M. Nakada H. Nakamura E. Ikeda, et al. 1999 Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors Am J Pathol 154 417 428 1:CAS:528:DyaK1MXjtVCqsbc%3D 10027400
13. E.R. Smith D. Zurakowski A. Saad, et al. 2008 Urinary biomarkers predict brain tumor presence and response to therapy Clin Cancer Res 14 2378 2386 1:CAS:528:DC%2BD1cXkvFGmtbw%3D 10.1158/1078-0432.CCR-07-1253 18413828 (Pubitemid 351551071)
14. A. Lucio-Eterovic Y. Piao J.F. de Groot 2009 Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy Clin Cancer Res 15 4589 4599 1:CAS:528:DC%2BD1MXosV2lt7Y%3D 10.1158/1078-0432. CCR-09-0575 19567589
15. R.K. Jain D.G. Duda C.G. Willett, et al. 2009 Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 327 338 1:CAS:528:DC%2BD1MXms12gtb4%3D 10.1038/nrclinonc.2009.63 19483739
16. T.T. Batchelor A.G. Sorensen E. di Tomaso, et al. 2007 AZD2171, a pan-VEGF receptor thyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 1:CAS:528:DC%2BD2sXhtFClsLc%3D 10.1016/j.ccr.2006.11.021 17222792 (Pubitemid 46075199)
17. A. Saidi M. Hagedorn N. Allain, et al. 2009 Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness Int J Cancer 125 1054 1064 1:CAS:528: DC%2BD1MXovVersrY%3D 10.1002/ijc.24380 19431143